Venous Embolism of Lower Extremities (Diagnosis)NCT07335341
Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System
An observational study of Venous Embolism of Lower Extremities (Diagnosis) and Arterial Embolism and Thrombosis, run by Medtronic Endovascular at 4 sites in United States.
Trial summary
The purpose of Case-Specific Health Care Professional (HCP) Clinical Survey of Liberant™ Thrombectomy System, also known as the Liberant Clinical Assessment, is to collect first-in-human clinical data to confirm the safety and performance of the Medtronic Liberant™ thrombectomy system when used for the removal of… Read more about this study
- Who is it for?
- Ages 22 years and older
- Conditions the study is for
- Venous Embolism of Lower Extremities (Diagnosis), Arterial Embolism and Thrombosis, Acute DVT of Lower Extremity
- What is being tested?
- Liberant Thrombectomy System
- Type of treatment
- Medical device
- How many people
- 50 participants
- Where
- 4 sitesUnited States
- Study dates
- 24 Feb 2026to Oct 2026
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The Liberant thrombectomy system is intended for use in adult patients with occluded peripheral arterial and venous vessels.
Patient case selection to be included in the clinical assessment will be specific to Liberant and will be made according to the following criteria:
- Patient treated is age ≥ 22 years at the time of procedure
- Use of Liberant in accordance with the device labeling within 72 hours of index procedure
Trial locations and contacts
4 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Elizabeth Hunt contact
United States4 sites, 4 recruiting
- Recruiting
Naples Comprehensive Health
Naples, Florida, 34108
Manasa Gudipally
- Recruiting
Mount Sinai
New York, New York, 10029
Manasa Gudipally, manasa.gudipally@medtronic.com
- Recruiting
Baylor Heart Hospital Of Plano
Plano, Texas, 75093
Manasa Gudipally, manasa.gudipally@medtronic.com
- Recruiting
MedStar Health
Washington D.C., District of Columbia, 003329
Manasa Gudipally
About this study
The purpose of Case-Specific Health Care Professional (HCP) Clinical Survey of Liberant™ Thrombectomy System, also known as the Liberant Clinical Assessment, is to collect first-in-human clinical data to confirm the safety and performance of the Medtronic Liberant™ thrombectomy system when used for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems
Read the detailed description
The Liberant Clinical Assessment is a multicenter, prospective per patient HCP recollection survey. Participating HCPs will document their individual case experience following routine utilization of Liberant in accordance with the approved device labeling. Individual use cases will be entered within 72 hours of device usage to identify periprocedural incidents of risk and evaluate device performance. At least 50 use cases will be collected and aggregated from at least 10 participating HCPs. This data collection is for a single point in time, with no patient follow-up. Individual HCP responses for each case will be aggregated by a third party vendor.
- Conditions
- Venous Embolism of Lower Extremities (Diagnosis), Arterial Embolism and Thrombosis, Acute DVT of Lower Extremity, Chronic DVT of Lower Extremity, DVT, Deep Vein Thrombosis Leg
- Being tested
- Liberant Thrombectomy System
- Keywords
- Thrombus in Peripheral Arterial Systems, Thrombectomy, Thrombosis, Venous Thrombosis, Aspiration Thrombectomy, Percutaneous Mechanical Thrombectomy, Arterial Occlusive Diseases, Vascular Diseases, Peripheral Vascular Diseases, Peripheral Arterial Disease, Mechanical Thrombectomy, Aspiration, Liberant Thrombectomy System, adverse events, Excipio, Thrombus in Peripheral Venous Systems
- Medical subject headings
- Disease, Thrombosis, Venous Thrombosis, Peripheral Arterial Disease, Arterial Occlusive Diseases, Vascular Diseases, Peripheral Vascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Liberant Thrombectomy SystemDevice
The Liberant thrombectomy system is indicated for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of Device related Serious Adverse Event at Index procedure
An Adverse Event that converted to Serious Adverse Event, involving the function of the subject device, or the presence of the device in the body, including events that are directly attributable to the Liberant Thrombectomy System
Measured: Index Procedure
Rate of technical success at Index procedure
Technical success: Successful introduction, delivery, aspiration of fresh, soft emboli or thrombi, and retrieval of the Liberant per the Instructions for Use (IFU) during the index procedure
Measured: Index procedure
Rate of Procedural Success at Index procedure
Procedure success: Successful removal of fresh, soft emboli or thrombi and restoration of adequate blood flow, inclusive of all endovascular therapies during the index procedure
Measured: Index procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2026
- Study start24 Feb 2026
- Primary completionOct 2026 (estimated)
- Study completionOct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Venous Embolism of Lower Extremities (Diagnosis)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Medtronic Endovascular
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- John R Laird Jr, MD, Principal investigator, Medtronic Endovascular
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07335341
- Sponsor's protocol ID
- MDT25034
- Status last verified
- Aug 2026
- First submitted
- 5 Jan 2026
- Last updated
- 11 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No: No patients will be engaged, and no medical records will be accessed or used. Individual HCP responses for each case will be aggregated into a final report.